Cogstate Ltd CGS
ASX · Australia · Commercial Services
AUD 3.40-0.01 (-0.29%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Cogstate CEO and MD Brad O’Connor talked with Proactive at the ASX Small and Mid-Cap Conference about its central nervous system trials, its defining FY26 and what’s to come in FY27. Cogstate Ltd (ASX: CGS) is a neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support partners in the delivery of electronic clinical outcome assessment (eCOA) soluti
Revenue up 15% to nearly $61 million with new sales contracts surging 116% year-over-year, driving record contracted future revenue of $118.5 million.
As the Australian share market experiences a slight dip, with futures showing a -0.15% decline amidst global economic uncertainties and geopolitical tensions, investors are keeping a close eye on potential growth opportunities. In such fluctuating conditions, companies with high insider ownership can be appealing as they often indicate strong confidence from those who know the business best, making them noteworthy contenders for those seeking resilient investments in today's market landscape.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.